BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Okita K, Okazaki S, Uejima S, Yamada E, Kaminaka H, Kondo M, Ueda S, Tokiwa R, Iwata N, Yamasaki A, Hayashi N, Ogura D, Hirotani K, Yoshioka T, Inoue M, Masuko K, Masuko T. Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers. Oncotarget 2020;11:31-45. [PMID: 32002122 DOI: 10.18632/oncotarget.27414] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Hihara F, Matsumoto H, Yoshimoto M, Masuko T, Endo Y, Igarashi C, Tachibana T, Shinada M, Zhang M, Kurosawa G, Sugyo A, Tsuji AB, Higashi T, Kurihara H, Ueno M, Yoshii Y. In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study. IJMS 2022;23:5807. [DOI: 10.3390/ijms23105807] [Reference Citation Analysis]
2 Hassani D, Jeddi-Tehrani M, Yousefi P, Mansouri-Fard S, Mobini M, Ahmadi-Zare H, Golsaz-Shirazi F, Amiri MM, Shokri F. Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies. Cancer Chemother Pharmacol 2022. [PMID: 35079876 DOI: 10.1007/s00280-021-04390-3] [Reference Citation Analysis]
3 Okita K, Imai K, Kato K, Sugiura R, Endo Y, Masuko K, Tomioka Y, Masuko T. Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of HER1-or HER2-targeted drugs. Biochem Biophys Res Commun 2021;576:59-65. [PMID: 34482024 DOI: 10.1016/j.bbrc.2021.08.091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Hayashi N, Yamasaki A, Ueda S, Okazaki S, Ohno Y, Tanaka T, Endo Y, Tomioka Y, Masuko K, Masuko T, Sugiura R. Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target. Oncotarget 2021;12:1256-70. [PMID: 34194623 DOI: 10.18632/oncotarget.27981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Okita K, Hara Y, Okura H, Hayashi H, Sasaki Y, Masuko S, Kitadai E, Masuko K, Yoshimoto S, Hayashi N, Sugiura R, Endo Y, Okazaki S, Arai S, Yoshioka T, Matsumoto T, Makino Y, Komiyama H, Sakamoto K, Masuko T. Antitumor effects of novel mAbs against cationic amino acid transporter 1 (CAT1) on human CRC with amplified CAT1 gene. Cancer Sci 2021;112:563-74. [PMID: 33211385 DOI: 10.1111/cas.14741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]